Literature DB >> 25886921

Implementation and Operational Research: Effect of Universal Access to Antiretroviral Therapy on HIV/AIDS Mortality in Mexico 1990-2011.

Juan E Hernández-Ávila1, Lina S Palacio-Mejía, Alfonso Hernández-Romieu, Sergio Bautista-Arredondo, Jaime Sepúlveda Amor, Mauricio Hernández-Ávila.   

Abstract

INTRODUCTION: Universal coverage of highly active antiretroviral therapy (HAART) for HIV/AIDS in Mexico was achieved in a staggered fashion. First, HAART was made available in 1997 for employees in the formal sector and subsequently, in 2003, for informal sector workers and the unemployed population. We evaluated the impact of this free universal HAART program on HIV/AIDS mortality in the Mexican population aged 15 years or older.
METHODS: Time-series cross-sectional data analysis of standardized HIV/AIDS mortality rates (1990-2011) using marginal linear models with inflection points at 1994, 1997, and 2003.
RESULTS: Men employed in the formal sector experienced the greatest effect of access to HAART, with a 32% reduction in mortality from 1997 to 2011 (P < 0.01). For men in this sector, mortality increased from 1990 to 2003, then stabilizing at 7 deaths per 100,000. For women in the informal sector, mortality increased from 1990 to 2011. We found large between-state variability: mortality decreased by 59% in Mexico City while it increased by 245% in Tabasco during the study period. Six of 32 states achieved statistically significant reductions in mortality while 5 states continued to experience increasing mortality rates despite universal HAART.
CONCLUSIONS: Access to universal HAART has had relative success in Mexico. The heterogeneity of HIV/AIDS mortality by employment status, gender, and state of residence highlight urgent needs to improve health equity with pro-poor and gender-responsive programs and a call for country-specific operational research in HIV/AIDS prevention and treatment. Our results may apply to other countries seeking to implement universal access to antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25886921     DOI: 10.1097/QAI.0000000000000645

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  5 in total

1.  Life expectancy of HIV-infected patients followed at the largest hospital in Guinea-Bissau is one-fourth of life expectancy of the background population.

Authors:  Thomas Engell-Sørensen; Andreas Rieckmann; Candida Medina; David da Silva Té; Amabelia Rodrigues; Ane Bærent Fisker; Peter Aaby; Christian Erikstrup; Sanne Jespersen; Christian Wejse; Bo Langhoff Hønge
Journal:  Infection       Date:  2021-02-02       Impact factor: 3.553

2.  The Population Impact of Late Presentation With Advanced HIV Disease and Delayed Antiretroviral Therapy in Adults Receiving HIV Care in Latin America.

Authors:  Pablo F Belaunzarán-Zamudio; Yanink N Caro-Vega; Bryan E Shepherd; Peter F Rebeiro; Brenda E Crabtree-Ramírez; Claudia P Cortes; Beatriz Grinsztejn; Eduardo Gotuzzo; Fernando Mejia; Denis Padgett; Jean W Pape; Vanessa Rouzier; Valdilea Veloso; Sandra Wagner Cardoso; Catherine C McGowan; Juan G Sierra-Madero
Journal:  Am J Epidemiol       Date:  2020-06-01       Impact factor: 4.897

3.  Cost-Effectiveness of Combined Sexual and Injection Risk Reduction Interventions among Female Sex Workers Who Inject Drugs in Two Very Distinct Mexican Border Cities.

Authors:  Jose L Burgos; Thomas L Patterson; Joshua S Graff-Zivin; James G Kahn; M Gudelia Rangel; M Remedios Lozada; Hugo Staines; Steffanie A Strathdee
Journal:  PLoS One       Date:  2016-02-18       Impact factor: 3.752

4.  Factors associated with program effectiveness in the implementation of a sexual risk reduction intervention for female sex workers across Mexico: Results from a randomized trial.

Authors:  Eileen V Pitpitan; Shirley J Semple; Gregory A Aarons; Lawrence A Palinkas; Claudia V Chavarin; Doroteo V Mendoza; Carlos Magis-Rodriguez; Hugo Staines; Thomas L Patterson
Journal:  PLoS One       Date:  2018-09-11       Impact factor: 3.240

Review 5.  HIV treatment in Guinea-Bissau: room for improvement and time for new treatment options.

Authors:  S Jespersen; F Månsson; J Lindman; C Wejse; C Medina; Z J da Silva; DdS Te; P Medstrand; J Esbjörnsson; B L Hønge
Journal:  AIDS Res Ther       Date:  2020-02-04       Impact factor: 2.250

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.